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Purpose: Using exome sequencing, the underlying variants in
many persons with autosomal recessive diseases remain undetected.
We explored autosomal recessive Stargardt disease (STGD1) as a
model to identify the missing heritability.
Methods: Sequencing of ABCA4 was performed in 8 STGD1 cases
with one variant and p.Asn1868Ile in trans, 25 cases with one
variant, and 3 cases with no ABCA4 variant. The effect of intronic
variants was analyzed using in vitro splice assays in HEK293T cells
and patient-derived fibroblasts. Antisense oligonucleotides were
used to correct splice defects.
Results: In 24 of the probands (67%), one known and five novel
deep-intronic variants were found. The five novel variants resulted
in messenger RNA pseudoexon inclusions, due to strengthening of
cryptic splice sites or by disrupting a splicing silencer motif. Variant
c.769-784C>T showed partial insertion of a pseudoexon and was
found in cis with c.5603A>T (p.Asn1868Ile), so its causal role could
not be fully established. Variant c.4253+43G>A resulted in partial
skipping of exon 28. Remarkably, antisense oligonucleotides
targeting the aberrant splice processes resulted in (partial) correc-
tion of all splicing defects.
Conclusion: Our data demonstrate the importance of assessing
noncoding variants in genetic diseases, and show the great potential
of splice modulation therapy for deep-intronic variants.
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INTRODUCTION
In the past decade, next-generation sequencing (NGS) has
enabled a rapid identification of novel disease genes,1–3 and
transformed molecular diagnostic testing.4–6 Thus far, the
emphasis was on coding and flanking splice site sequences
that harbor the majority of genetic defects. Herewith, the
underlying defects could be identified in ~50% of individuals
with genetically heterogeneous diseases, including inherited
retinal diseases (IRDs).7–9 Genome sequencing can identify
the majority of noncoding sequence variants,1 but it will be
very challenging to pinpoint the causal variants in the absence
of assays that reveal the resulting messenger RNA (mRNA)
and/or protein defects.
For diseases that are due to variants in a single gene, the
yield of variants generally exceeds 50%. This is true for
Stargardt disease (STGD1) (MIM 248200), which is caused by
pathogenic variants in the gene encoding the adenosine
triphosphate (ATP) binding cassette type A4 (ABCA4)
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(MIM 601691)10 as biallelic variants can be found in the
majority of the cases11 and in a smaller proportion of other
IRD subtypes.12–14 In ~30% of STGD1 cases, however, the
expected second ABCA4 variant was lacking. A frequent
coding variant, p.Asn1868Ile, was present in ~10% of STGD1
cases who had a severe pathogenic variant in trans and who
generally showed late-onset disease.15,16 The remaining
pathogenic variants in ABCA4 rarely consist of heterozygous
deletions,17–19 whereas deep-intronic ABCA4 variants also
account for some of the missing heritability in
STGD1.11,17,20,21 By employing STGD1-derived keratinocytes,
it was shown that some of these variants strengthen cryptic
splice sites or create new splice sites, ultimately resulting in
pseudoexon (PE) inclusions.21 Using STGD1-derived photo-
receptor precursor cells (PPCs), we recently showed that two
intronic variants in ABCA4 (c.4539+2001G>A and c.4539
+2028C>T) strengthen exonic splice enhancer elements
(ESEs), resulting in the inclusion of a 345-nt PE.22
PE inclusions due to deep-intronic variants are attractive
targets for antisense oligonucleotide (AON)-based splicing
correction.23 In the field of IRDs, these molecules have
shown therapeutic potential for deep-intronic pathogenic
variants in CEP290,24–27 USH2A,28 or OPA1,29 and a phase
1/2 clinical trial using AONs to treat CEP290-associated
Leber congenital amaurosis is ongoing (NCT03140969).
In this study, we employed STGD1 as a model to assess the
challenges to identify pathogenic noncoding variants. We
sequenced the ABCA4 locus in 36 STGD1 individuals with
one ABCA4 variant and p.Asn1868Ile in trans (n= 8), one
ABCA4 variant (n= 25), or no (n= 3) ABCA4 variants.
Selected noncoding variants were tested by in vitro splice
assays or using STGD1-derived fibroblasts. Subsequently,
several AONs were designed and successfully applied to
redirect erroneous splicing.
MATERIALS AND METHODS
Samples
Written informed consent was obtained prior to participation
in the study, which adhered to the Declaration of Helsinki.
This study was approved by the Medical Ethical Committee
2010-359 (Protocol nr. 2009-32; NL nr. 34152.078.10) and the
Commissie Mensgebonden Onderzoek Arnhem-Nijmegen
(Dossier no. 2015-1543; dossier code sRP4h). More informa-
tion regarding the proband cohort, and details of the materials
and methods used, are provided in the Supplementary
Material.
ABCA4 sequence analysis and selection of candidate splice
variants
Detailed information of the selection of candidate splice
variants and inclusion criteria is provided in the Supplemen-
tary Material.
Midigene-based splice assay
The effect of 11 noncoding variants was assessed by midigene-
based splicing assays employing seven wild-type (WT) BA
clones described previously30 and the newly designed BA30.
WT and mutant constructs were transfected in HEK293T cells
and the extracted total RNA was subjected to reverse
transcription polymerase chain reaction (RT-PCR) (Table S1)
as described previously.30
Single-molecule molecular inversion probe–based sequence
analysis of intronic ABCA4 regions
To test the occurrence of five intronic ABCA4 variants (c.769-
784C>T, c.859-506G>C, c.4253+43G>A, c.4539+1100A>G,
c.4539+1106C>T) in 412 genetically unsolved STGD1 cases
from France (n= 224) or Germany (n= 188), we designed
single-molecule molecular inversion probes (smMIPs) based
on a previously developed cost-effective sequencing proto-
col.31 The variant calling and annotation was performed using
an in-house pipeline. The number of single-molecule
consensus reads ranged from 14 to 1587, with an average
coverage of 489x.
Antisense oligonucleotides
For each deep-intronic variant that caused PE inclusion, three
AONs were designed (Table S2). The design of the therapeutic
molecules was performed as described elsewhere.32 Oligonu-
cleotides had a phosphorothioate backbone with a 2-O-
methyl sugar modification (2OMe/PS) and were synthesized
by Eurogentec. The oligonucleotides were resuspended in
phosphate-buffered saline (PBS) and used at a concentration
of 0.5 µM.
In vitro rescue studies in HEK293T cells using midigenes and
AONs
HEK293T cells were transfected with either the wild-type or
the mutant construct. Twenty-four hours posttransfection,
each well was subdivided in five wells to be transfected with
the respective AON, the sense oligonucleotide (SON), or left
untransfected (NT). Forty-eight hours post-AON delivery,
cells were harvested and RNA analysis was performed by RT-
PCR. All experiments were performed in two independent
replicates. Primer sequences can be found in Table S1.
Rescue studies using antisense oligonucleotides in
fibroblasts
Fibroblast cells were transfected with each of the antisense
oligonucleotides, or transfected with empty liposomes (NT).
Forty-four hours posttransfection, medium was removed and
medium containing cycloheximide (CHX) was added to block
nonsense-mediated decay (NMD). Four hours later, cells were
harvested and subjected to RNA analysis by RT-PCR. All
experiments were performed in two independent replicates.
Primer sequences are indicated in Table S1.
Capillary analysis
To quantify the ratios between correct and aberrant
transcripts we loaded the RT-PCR samples onto a Fragment
Analyzer Auto Capillary Electrophoresis System (Advanced
Analytical Technologies, Inc.). Analysis of the peaks was
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performed using the corrected peak area parameter and only
the peaks corresponding to the expected bands were taken
into account.
RESULTS
Identification and selection of deep-intronic variants for
splicing assay
Haloplex sequencing of eight STGD1 cases carrying one
causal ABCA4 variant and p.Asn1868Ile in trans, 22 STGD1
cases with only one, and two cases carrying no ABCA4
variant, yielded 220 rare ABCA4 variants (allele frequency
[AF] ≤0.01 in control individuals), consisting of 85 indepen-
dent novel variants (Table S3). In the four British STGD1
cases with one (n= 3) or no (n= 1) ABCA4 variant analyzed
by genome sequencing, eight novel rare (AF ≤0.01)
independent ABCA4 variants remained (Table S3).
Eleven noncoding variants were selected for splice assays
(Table S4). Seven of these (c.768+7329A>G, c.858+526T>G,
c.859-506G>C, c.1555-5008C>T, c.4539+1100A>G, c.4539
+1106C>T, c.6148-421T>C) were selected as they were
located at cryptic splice sites or created a new putative splice
site with a relative strength of at least 75% of the maximal
score in two of five algorithms, and showed an increased
splice prediction score of at least 2% (Table S4). Two variants,
c.769-784C>T and c.4253+43G>A, belonging to three alleles
(c.[769-784C>T; 5603A>T], c.[4253+43G>A; 6006-609T>A],
c.[4253+43G>A; 5603A>T]), were enriched among the
monoallelic cases, i.e., in 7 and 9 of 36 probands, respectively.
The c.4253+43G>A variant was reported previously.33
Finally, the c.1937+435C>G variant was selected because it
was located in the genomic sequence of an alternate exon in
intron 13 (Chr1: 94,527,737–94,527,644).21
Four novel deep-intronic variants result in PE generation
through the strengthening of splice sites
To test the functional effect of the 11 selected noncoding
variants, seven ABCA4 wild-type midigene constructs pre-
viously described as BA4, BA6, BA7, BA9, BA11, BA19, and
BA2130 and the newly designed BA30 (Table S5) were
mutagenized. Upon RT-PCR and Sanger sequence validation,
four variants had no effect (Figure S1). Variant c.858
+526T>G did not show a PE insertion, but did yield four
weak smaller fragments (Figure S1), the relevance of which is
unknown in the absence of sequence results. This variant was
found in cis with a complex allele containing a protein-
truncating pathogenic variant (p.[Trp273*; Asn1868Ile]) in
individual E-II:1, as determined by segregation analysis. The
remaining six variants resulted in clear splice defects (Fig. 1,
Figure S2) that allowed us to detect the second variant in 15/
26 monoallelic probands, two deep-intronic variants in 2/3
cases without ABCA4 variants, and a complex allele (c.[769-
784C>T; 5603A>T]) in seven STGD1 cases carrying one
deep-intronic variant. Considering that these variants or
complex alleles are causal, segregation was as expected
(Table 1). The remaining 12 unsolved STGD1 cases are listed
in Table S6.
The deep-intronic variant c.769-784C>T, present in 7/36
STGD1 cases, is located in intron 6, and was predicted to
increase the strength of an intronic splice acceptor site at
position g.94,549,775. In addition, a strong splice donor site
was situated 161 nt downstream. RT-PCR analysis using wild-
type and mutant minigene constructs revealed that, compared
with the wild-type construct, the mutant c.769-784C>T
construct showed an additional band of 296 bp, containing
a 162-nt PE (Fig. 1b, Figure S2). Quantification of mutant
mRNA in transfected HEK293T cells revealed that the PE
fragment only accounted for ~8% of the total ABCA4 pre-
mRNA (Table S7), suggesting a mild effect at the RNA and
thus protein level (r.[=, 768_769ins(162)]; p.[=,
Leu257Aspfs*3]).
The deep-intronic variant c.859-506G>C was predicted to
significantly strengthen a cryptic intronic splice acceptor site
and is accompanied by a downstream splice donor site. This
variant resulted in a 56-nt PE insertion (Fig. 1b, Figure S2),
which accounted for 75.5% of total splice products (Table S7),
indicating the highly deleterious effect of this variant at the
RNA and (predicted) protein level (r.[858_859ins(56), =];
p.[Phe287Thrfs*32, =]).
Deep-intronic variants c.4539+1100A>G and c.4539
+1106C>T were predicted to alter the same cryptic splice
donor site located at position g.94,493,901. A very strong
splice acceptor site was located at g.94,493,968. Besides the
expected 68-nt PE fragment (PE30.1) due to the splice
acceptor site at position c.4539+1033 and the splice donor
site at position c.4539+1100, an additional 112-nt PE
(PE30.2) carrying the same splice donor but another acceptor
site located at g.94,494,012 was observed (Fig. 1b, Figure S2).
Interestingly, the relative ratios of these two PEs significantly
differed between the midigene constructs carrying c.4539
+1100A>G or c.4539+1106C>T. PE30.1 accounted for 60.6%
and 93.1% of the total transcript in c.4539+1100A>G or
c.4539+1106C>T respectively, while PE30.2 was present in
20.1% and 3.8% of the complementary DNA (cDNA)
products, respectively (Table S7). Because both c.4539
+1100A>G and c.4539+1106C>T showed only a minor
fraction of correctly spliced products (19.2% and 3.0%) and
because PE30.1 and PE30.2 are both predicted to lead to a
frameshift, these variants were both deemed to have a
severe effect (r.[4539_4540ins(68), 4539_4540ins(112), =];
p.[Arg1514Glyfs*3, Arg1514Valfs*31, =]) (Table 1, Table S8).
c.1937+435C>G results in PE generation through the
disruption of putative splice silencers
The c.1937+435C>G variant did not alter the strength of a
cryptic splice site. Instead, it was predicted to disrupt an ESE
(SC35) motif, and, more importantly, to inactivate two splice
silencer motifs and to lower the predicted strength of a third
one (Figure S3). This variant was located within the genomic
sequence of a low-abundance ABCA4 transcript that contains
intron 13 sequences.21 RT-PCR analysis revealed a 134-nt PE
insertion between positions c.1937+396 and c.1937+529 in
mutant BA11 compared with WT (Fig. 1b, Figure S2).
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Although the splice defect caused by this variant disrupted the
reading frame (r.[=, 1937_1938ins(134)]; p.[=, Ser646-
Serfs*25]), the fraction of mutant transcript was low (8.6%)
(Table S7).
Variant c.4253+43G>A results in exon skipping through the
disruption of putative splice silencers
The c.4253+43G>A variant was present in eight monoallelic
STGD1 individuals and in one proband carrying a causal
variant and p.Asn1868Ile in trans. It does not weaken the
splice donor site of exon 28, nor does it affect any other
cryptic splice sites in silico. It does affect the strength of
several splice enhancer or silencer motifs (Figure S4). The
c.4253+43G>A variant was found in cis with the previously
reported c.6006-609T>A11 in eight of nine probands, but
c.6006-609T>A showed no effect in an in vitro splice assay
(Figure S2). The c.4253+43G>A mutant yielded bands of 495
and 370 bp, the first corresponding to the correctly spliced
product, and the second to a product in which exon 28 was
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Fig. 1 Generation and assessment of splicing defects using midigenes. a Schematic representation of the five wild-type midigenes used that were
cloned between exons 3 and 5 of Rhodopsin in pCI-Neo-RHO. Positions of the variants present in six mutant midigenes are indicated. b Assessment of the
splicing defects upon midigene transfection in HEK293T cells. Five pseudoexon (PE) inclusions and one exon skipping event were detected in the mutant
(MUT) constructs compared to the wild-type (WT). MQ stands for the negative control of the polymerase chain reaction (PCR). Rhodopsin (RHO) amplifi-
cation was used as a transfection and loading control.
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skipped (Fig. 1b, Figure S2). This 125-nt deletion is predicted
to lead to a frameshift, and although both WT and mutant
midigenes showed some skipping of exon 28, in the mutant
construct this was significantly higher compared with WT
(26.1% vs. 2.8%, Table S7). The fact that in all nine probands,
a severe variant was found in trans, in combination with a late
age of onset, suggests a mild effect of this variant (r.[=,
4129_4253del(125)]; p.[=, Ile1377Hisfs*3]). An overview of
the allele frequencies and of the splice defects caused by all six
variants can be found in Tables S8 and S9.
smMIP-based sequence analysis of intronic ABCA4 regions
Five of six intronic ABCA4 variants were analyzed for their
recurrence in 412 genetically unsolved STGD1 cases from France
(n= 224) or Germany (n= 188), by employing smMIPs.31
Three variants were found in a heterozygous state in this cohort:
c.769-784C>T (n= 4), c.4253+43G>A (n= 29), and c.4539+
1106C>T (n= 1) (Table S8 and Table S9), whereas variants
c.859-506G>C and c.4539+1100A>G were not detected.
Antisense oligonucleotide-based exclusion of PEs
For five variants (c.769-784C>T, c.859-506G>C, c.1937
+435C>G, c.4539+1100A>G, and c.4539+1106C>T), we
designed three different AONs each that aim to result in PE
exclusion. For c.4253+43G>A, only two AONs were
designed, aiming to block splice silencer motifs to reinforce
inclusion of exon 28. A summary of the sequences and
characteristics of the AONs is provided in Table S2. The effect
of the AONs at the RNA level was assessed by RT-PCR and
subsequently semiquantified using capillary analysis (Fig-
ure S5, Table S7).
For c.769-784C>T, AON2 completely restored correct
splicing, whereas AON3 had a partial effect (Fig. 2b). When
using AON1, also some splice redirection was observed; an
additional faint band was present both in WT and mutant.
Cloning and sequence analysis of this band revealed that the
5’ 68 nt of the PE were skipped, while the 3’ 94 nt remained.
Given the position of AON1, this AON most likely blocks the
splice acceptor site of the PE, triggering the use of a
downstream splice acceptor site. For c.859-506G>C, two
AONs (AON1 and AON3) corrected the splicing defect
(Fig. 2b). For c.1937+435C>G, all three AONs restored
normal splicing (Fig. 2b). In addition, we observed that the
134-nt PE could also naturally be included in the WT
construct, as the band was also present in the nontreated and
the SON-treated samples. Since the PE is also inserted when
transfecting the WT construct, the variant apparently
enhances PE recognition. Finally, for the two neighboring
variants c.4539+1100A>G and c.4539+1106C>T, AON1 and
AON2 correctly restored splicing, while AON3 did not show
any rescue (Fig. 2b).
AON-based PE exclusion using STGD1-derived fibroblast
cells
To investigate whether the AON-based splice corrections
observed in the midigene assays would also occur in patient-
derived cells, we generated fibroblast cell lines from a
proband carrying c.[769-784C>T; 5603A>T] and c.1822T>A
(p.Phe608Ile) (patient A-I:2), and from a STGD1 proband
carrying c.859-506G>C and a putative deletion on the other
allele encompassing intron 7 (case DNA14-33085; not listed
in Table 1). For both cases, the same PEs were detected as in
the midigene assays (Fig. 3), yet a larger amount of PE-
containing mRNA was detected in fibroblasts from A-I:2
grown under NMD-suppressing conditions (18.2%) com-
pared with HEK293T-transfected cells (8.6%). Considering
that this STGD1 individual carries a missense variant
(p.Phe608Ile), the amount of PE-containing mRNA from
the c.769-784C>T allele likely is much higher than 18%. The
same AONs that restored splicing in the midigenes also
showed rescue in fibroblasts (Fig. 3). For c.769-784C>T,
AON2 was the most effective, correcting 100% of the
transcripts, whereas AON3 also showed a strong rescue
(Fig. 3, Figure S6, Table S10). AON1 also resulted in PE
skipping but induced an alternative splicing event. Interest-
ingly, the insertion of this partial PE was also detected in
control fibroblasts. Sequence analysis revealed that the upper
band of the artifact corresponded to the partial PE, while the
lower was a heteroduplex consisting of the WT and partial
PE-containing transcripts. ABCA4 mRNA was also barely
detected in the fibroblasts carrying c.859-506G>C when they
were not subjected to CHX treatment (Fig. 3). After CHX
incubation, a 56-nt PE was detected that, upon delivery of
AON1 and AON3, was almost completely absent from the
transcripts.
AON-based exon inclusion
To correct the splice defect of c.4253+43G>A, AONs were
designed to promote exon 28 inclusion. Two AONs were
delivered to the midigene-transfected HEK293T cells. To
assess whether the AON was inducing the inclusion of exon
28, the ratio between correct and Δexon 28 transcript was
calculated with Fiji, or using the corrected peak area obtained
in the capillary analysis (Figure S5). Using both methods,
AON2 was shown to induce ~10% extra inclusion of exon 28
(Fig. 2), whereas for AON1, splice redirection was less evident
(Table S7).
DISCUSSION
To identify missing noncoding variants in STGD1 cases, we
sequenced the ABCA4 locus in 36 probands and identified
one known and five novel intronic variants in 24 (67%)
probands. Four novel deep-intronic variants (c.769-784C>T,
c.859-506G>C, c.4539+1100A>G, c.4539+1106C>T)
strengthen cryptic splice sites at noncanonical nucleotide
positions and thereby result in PE insertions, contrary to most
of the published deep-intronic splice site variants that create
canonical splice sequences.34,35 Variant c.1937+435C>G
disrupted a splicing silencer motif that is located within a
low-expressed alternate exon, and resulted in a 134-nt PE
formation.21 This PE contains a proper splice acceptor site
but, similar to the alternate exon, no consensus splice donor
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site sequence. The c.4253+43G>A variant disrupted predicted
splice silencers and created an ESE, and led to partial skipping
of the upstream exon 28. Interestingly, we identified two
probands (M-II:1 and P-II:3) that carried deep-intronic
variants on both alleles.
All novel variants were predicted to result in protein
truncation, but two variants, c.769-784C>T and c.4253
+43G>A, found in seven and nine probands, respectively,
only affect a small proportion of the mRNA. Testing of 412
other genetically unexplained STGD1 cases revealed 29
persons to carry c.4253+43G>A and four cases to carry
c.769-784C>T. AONs were able to (partially) correct the
observed splice defects for all variants in HEK293T cells and,
for two variants, in STGD1-derived fibroblasts.
Fourteen first alleles in the 24 probands carry protein-
truncating variants and are thus assumed to have a severe
effect (Table 1). For other missense or complex alleles, the
severity is less clear. Based on previous studies,15,36,37 our
mRNA analysis of the deep-intronic variants, and the ages at
onset of the STGD1 probands described here, we can
hypothesize on the severity of the intronic variants. The
c.859-506G>C, c.4539+1100A>G, and c.4539+1106C>T
variants all show PE insertion in the majority of ABCA4
transcripts and can thus be considered severe variants. This
correlates very well with an age at onset ≤10 years when found
in trans with a severe variant and between 15 and 49 years
when in trans with a mild variant (Table 1).
For c.1937+435C>G, the picture is more complicated. The
splice defect was mild, and the two probands carrying this
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variant carry either a severe variant p.(Leu257Valfs*17) (U-
II:1) or a mild allele p.[Gly863Ala, Gly863del; Asn1868Ile] (T-
II:1) in trans. The ages of onset were 9 and 35 years,
respectively, which argues for a severe nature of c.1937
+435C>G in U-II:1 and a moderate-to-severe nature in T-
II:1. This is discordant with the observed partial PE insertion
in HEK293T cells. A similar observation was recently made
while studying the effect of c.4539+2001G>A and c.4539
+2028C>T.21 In STGD1-derived fibroblasts, mRNA analysis
did not show any PE insertion. In STGD1-derived photo-
receptor precursor cells however, we observed up to 15%
(c.4539+2028C>T) and 25% (c.4539+2001G>A) of PE-
containing mRNA.22 Based on their heterozygous presence
in the corresponding STGD1 cases and their moderate-to-
severe (c.4539+2028C>T) or severe (c.4539+2001G>A)
nature, about two times these percentages were expected.
We hypothesize that the photoreceptor precursor cells had
not yet reached a differentiation stage that closely mimics the
human retina situation. It is also of interest that, while c.1937
+435C>G is predicted to disrupt ESEs, c.4539+2001G>A and
c.4539+2028C>T are predicted to activate ESEs. Possibly, the
action of these splicing motifs requires specific factors that are
exclusively present in mature photoreceptors, while being
absent in HEK293T cell and explain the small effect for c.1937
+435C>G. Patient-derived photoreceptor-like cells may
reveal a more complete splice defect.
Recently, it was determined that c.2588G>C (p.[Gly863Ala,
Gly863del]) only acts as a penetrant pathogenic variant when
present in cis with c.5603A>T (p.Asn1868Ile).15 The common
p.(Asn1868Ile) variant was found as a second ABCA4 allele in
up to 50% of monoallelic STGD1 cases and is strongly
associated with late-onset STGD1.15 Upon Haloplex-based
ABCA4 gene sequencing, we found p.Asn1868Ile as a single
variant in trans with other (potentially) causal variants in 25/
65 (38%) of probands, who had an average age at onset of 42
years. In addition, we identified four biallelic but unaffected
persons and calculated that this variant, when present in trans
with a loss-of-function ABCA4 variant, shows a penetrance
<5%.16 Based on the relatively high frequency of c.769-
784C>T in non-Finnish European controls (AF 0.00426 in
gnomAD [http://gnomad.broadinstitute.org/]), its partial
effect on splicing, and the very late age of onset observed in
compound heterozygotes carrying c.[769-784C>T; 5603A>T]
(61.0 years; range: 38–69 years), we consider that c.769-
784C>T without c.5603A>T in cis may not be causative. We
therefore investigated the MAFs of the c.769-784C>T and
c.5603A>T variants (single and in combination) in 250
control Dutch families (GoNL: http://www.nlgenome.nl/).38
The single c.769-784C>T allele was found more often (6/998
alleles) than the c.[769-784C>T; 5603A>T] allele (2/998
alleles). The allele frequency of c.[769-784C>T; 5603A>T] in
our STGD1 patient cohort (n= 250), 0.014, is significantly
higher than in our general population (Chi-square test: p=
0.023; Bonferroni corrected). In two previous studies, the
mean ages at onset for STGD1 patients carrying c.5603A>T as
a single second allele in trans with severe ABCA4 variants
were 36 years15 and 42 years.16 The mean age of onset for
STGD1 patients carrying c.[769-784C>T; 5603A>T] is higher
than the age of onset of patients carrying the single
c.5603A>T variant (Mann–Whitney U; p<0.05). Given its
relatively small effect on mRNA splicing (18.2% PE inclusion
in mRNA from patient carrying this variant in a heterozygous
manner) and its invariable cis-configuration with c.5603A>T,
we cannot unequivocally assign pathogenicity to c.769-
784C>T. Possibly, patient-derived photoreceptor progenitor
cells may shed further light on this matter.
Interestingly, c.4253+43G>A also shows a relatively high
non-Finnish European AF (0.00598 in gnomAD). Although
c.4253+43G>A, with one exception (M-II:1), was found in cis
with c.6006-609T>A, we did not observe a splice defect for the
latter variant in vitro. This could be due to the lack of retina-
specific splice factors in the tested cells or due to another
missed deep-intronic variant that acts in concert with c.4253
+43G>A. In the one proband with c.4253+43G>A who
lacked c.6006-609T>A, the c.5603A>T (p.Asn1868Ile) variant
was found in cis. The age of onset of the cases carrying c.4253
+43G>A ranged from 18 to 61 years (average 41 years).
Interestingly, the earliest age at onset (18 years) was observed
in the proband M-II:1 who carried c.[4253+43G>A;
5603A>T].
The use of AONs to exclude PEs has been used for several
IRD-associated genes.24–29 However, in this study, several
technical challenges were observed. For the c.859-506G>C
variant, the design of the AONs was limited to very small
parts of the PE due to the repetitive nature of parts of the PE.
In case of the c.4539+1100A>G and c.4539+1106C>T
variants, we aimed to find effective AONs that would target
the PE for both variants. In addition, using midigenes for
c.769-784C>T, we observed variability between replicates,
probably due to differences in the transfection efficiencies or
passage of the cells. Nevertheless, for each variant, at least one
effective AON was discovered.17
Despite the significant yield of novel ABCA4 variants in this
study, a second ABCA4 variant was not detected in 11
monoallelic probands and there was one case with no ABCA4
variants, which could be due to (1) the presence of
heterozygous copy-number variations (CNVs), as only three
were tested using CNV analysis; (2) missed noncoding
variants residing in noncovered sequences; (3) too-stringent
selection criteria when using splicing algorithms; (4) incom-
plete sensitivity of the midigene in vitro splice assay; and (5)
genocopies in view of the high AF of ABCA4 variants (5–10%)
in the general population.18,36,39 Additional studies will be
needed to further unravel the missing heritability of STGD1.
In conclusion, we identified deep-intronic variants in 24/36
(67%) of STGD1 cases with no ABCA4 variants, one variant,
or one causal variant in trans with c.5603A>T. Two alleles (c.
[769-784C>T; 5603A>T] and c.4253+43G>A) are frequent in
our STGD1 cohort and appear to be associated with late-onset
STGD1. Due to its small effect on ABCA4 mRNA in
HEK293T cells and patient-derived fibroblasts, and its
invariable presence on the same allele as c.5603A>T, we
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could not establish causality for c.769-784C>T. Interestingly,
all the observed splice defects could be rescued with at least
one of the tested AONs, which provides a basis for the
development of new therapeutic strategies for individuals with
STGD1 carrying these variants.
SUPPLEMENTARY INFORMATION
The online version of this article (https://doi.org/10.1038/s41436-
018-0414-9) contains supplementary material, which is available
to authorized users.
ACKNOWLEDGEMENTS
We thank Ellen Blokland, Lonneke Duijkers, Duaa Elmelik, Anita
Hoogendoorn, Marlie Jacobs-Camps, Saskia van der Velde-Visser,
and Marijke Zonneveld-Vrieling for technical assistance. We thank
Sabine Defoort, Hélène Dollfus, Isabelle Drumare, Christian P.
Hamel, Karsten Hufendiek, Cord Huchzermeyer, Herbert Jägle,
Ulrich Kellner, Philipp Rating, Klaus Rüther, Eric Souied, Georg
Spital, and Xavier Zanlonghi for their cooperation and ascertain-
ing STGD1 cases. This work was supported by the FP7-PEOPLE-
2012-ITN programme EyeTN, agreement 317472 (to F.P.M.C.);
the Macula Vision Research Foundation (to F.P.M.C.); the
Foundation Fighting Blindness USA, grant no. PPA-0517-0717-
RAD (to A.G., C.B.H., F.P.M.C., R.W.J.C., and S.A.); the RP
Fighting Blindness UK (RetinaUK), grant no. GR591 (to F.P.M.C.
and S.A.); the Rotterdamse Stichting Blindenbelangen, the
Stichting Blindenhulp, and the Stichting tot Verbetering van het
Lot der Blinden (to F.P.M.C. and S.A.); and by the Landelijke
Stichting voor Blinden en Slechtzienden, Macula Degeneratie
fonds, and the Stichting Blinden-Penning, which contributed
through Uitzicht 2016-12 (to F.P.M.C. and S.A.). This work was
also supported by the Algemene Nederlandse Vereniging ter
Voorkoming van Blindheid, Stichting Blinden-Penning, Landelijke
Stichting voor Blinden en Slechtzienden, Stichting Oogfonds
Nederland, Stichting Macula Degeneratie Fonds, and Stichting
Retina Nederland Fonds, which contributed through UitZicht
2015-31, together with the Rotterdamse Stichting Blindenbelan-
gen, Stichting Blindenhulp, Stichting tot Verbetering van het Lot
der Blinden, Stichting voor Ooglijders, and Stichting Dowilvo (to
A.G. and R.W.J.C.); the Stichting Macula Degeneratie Fonds; and
the Stichting A.F. Deutman Researchfonds Oogheelkunde (to C.B.
H.). This work was also supported by the Algemene Nederlandse
Vereniging ter Voorkoming van Blindheid and Landelijke Stichting
voor Blinden en Slechtzienden, which contributed through
UitZicht 2014-13, together with the Rotterdamse Stichting
Blindenbelangen, Stichting Blindenhulp, and the Stichting tot
Verbetering van het Lot der Blinden (to F.P.M.C.), the Ghent
University Research Fund (BOF15/GOA/011), the Research Foun-
dation Flanders (FVO) G0C6715N, and the Hercules Foundation
AUGE/13/023 and JED Foundation to E.D.B. M.B. was PhD fellow
of the FWO and recipient of a grant of the funds for Research in
Ophthalmology (FRO). E.D.B. is Senior Clinical Investigator of the
FWO (1802215N). This work was also supported by the National
Institute for Health Research (NIHR) Biomedical Centre at
Moorfields and UCL Institute of Ophthalmology (to A.W.), UK
NIHR Rare Disease Translational Research Consortium (to G.A.
and A.W.), NIHR for the NIHR BioResource (RG65966) (to F.L.R.)
by grants from the Federal Ministry of Education and Research
(BMBF) (ref. IDs 01GM0851 and 01GM1108B) (to B.H.F.W.). G.A.
is supported by a Fight for Sight UK Early Career Investigator
Award. The funding organizations had no role in the design or
conduct of this research, and provided unrestricted grants. This
study made use of data generated by the Genome of the
Netherlands Project. Funding for the project was provided by the
Netherlands Organization for Scientific Research under award
number 184021007, dated 9 July 2009 and made available as a
Rainbow Project of the Biobanking and Biomolecular Research
Infrastructure Netherlands (BBMRI-NL). Samples where contrib-
uted by LifeLines (http://lifelines.nl/lifelines-research/general), the
Leiden Longevity Study (http://www.healthy-ageing.nl; http://
www.langleven.net), the Netherlands Twin Registry (NTR: http://
www.tweelingenregister.org), the Rotterdam studies (http://
www.erasmus-epidemiology.nl/rotterdamstudy), and the Genetic
Research in Isolated Populations program (http://www.epib.nl/
research/geneticepi/research.html#gip). The sequencing was car-
ried out in collaboration with the Beijing Institute for Genomics
(BGI).
DISCLOSURE
R.W.J.C., A.G., F.P.M.C., and S.A. are inventors on one or two
filed patents (nos. 16203864.0 and 18184432.5) that are related
to the contents of this manuscript. The other authors declare no
conflicts of interest.
Publisher’s note: Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional
affiliations.
REFERENCES
1. Carss KJ, Arno G, Erwood M, et al. Comprehensive rare variant analysis
via whole-genome sequencing to determine the molecular pathology of
inherited retinal disease. Am J Hum Genet. 2017;100:75–90.
2. Ng SB, Turner EH, Robertson PD, et al. Targeted capture and massively
parallel sequencing of 12 human exomes. Nature. 2009;461:272–276.
3. Nikopoulos K, Gilissen C, Hoischen A, et al. Next-generation sequencing
of a 40 Mb linkage interval reveals TSPAN12 mutations in patients with
familial exudative vitreoretinopathy. Am J Hum Genet.
2010;86:240–247.
4. Abu-Safieh L, Alrashed M, Anazi S, et al. Autozygome-guided exome
sequencing in retinal dystrophy patients reveals pathogenetic mutations
and novel candidate disease genes. Genome Res. 2013;23:236–247.
5. Beryozkin A, Shevah E, Kimchi A, et al. Whole exome sequencing reveals
mutations in known retinal disease genes in 33 out of 68 Israeli families
with inherited retinopathies. Sci Rep. 2015;5:13187.
6. Haer-Wigman L, van Zelst-Stams WA, Pfundt R, et al. Diagnostic exome
sequencing in 266 Dutch patients with visual impairment. Eur J Hum
Genet. 2017;25:591–599.
7. Gilissen C, Hehir-Kwa JY, Thung DT, et al. Genome sequencing identifies
major causes of severe intellectual disability. Nature. 2014;511:344–347.
8. Neveling K, Feenstra I, Gilissen C, et al. A post-hoc comparison of the
utility of Sanger sequencing and exome sequencing for the diagnosis of
heterogeneous diseases. Hum Mutat. 2013;34:1721–1726.
9. Neveling K, Collin RW, Gilissen C, et al. Next-generation genetic testing
for retinitis pigmentosa. Hum Mutat. 2012;33:963–972.
10. Allikmets R, Singh N, Sun H, et al. A photoreceptor cell-specific ATP-
binding transporter gene (ABCR) is mutated in recessive Stargardt
macular dystrophy. Nat Genet. 1997;15:236–246.
11. Zernant J, Xie YA, Ayuso C, et al. Analysis of the ABCA4 genomic locus in
Stargardt disease. Hum Mol Genet. 2014;23:6797–6806.
SANGERMANO et al ARTICLE
GENETICS in MEDICINE | Volume 0 | Number 0 | Month 9
12. Maugeri A, Klevering BJ, Rohrschneider K, et al. Mutations in the ABCA4
(ABCR) gene are the major cause of autosomal recessive cone-rod
dystrophy. Am J Hum Genet. 2000;67:960–966.
13. Cremers FP, van de Pol DJ, van Driel M, et al. Autosomal recessive retinitis
pigmentosa and cone-rod dystrophy caused by splice site mutations in
the Stargardt's disease gene ABCR. Hum Mol Genet. 1998;7:355–362.
14. Fakin A, Robson AG, Fujinami K, et al. Phenotype and progression of
retinal degeneration associated with nullizigosity of ABCA4. Invest
Ophthalmol Vis Sci. 2016;57:4668–4678.
15. Zernant J, Lee W, Collison FT, et al. Frequent hypomorphic alleles account
for a significant fraction of ABCA4 disease and distinguish it from age-
related macular degeneration. J Med Genet. 2017;54:404–412.
16. Runhart EH, Sangermano R, Cornelis SS, et al. The common ABCA4
variant p.Asn1868Ile shows nonpenetrance and variable expression of
Stargardt disease when present in trans with severe variants. Invest
Ophthalmol Vis Sci. 2018;59:3220–3231.
17. Bax NM, Sangermano R, Roosing S, et al. Heterozygous deep-intronic
variants and deletions in ABCA4 in persons with retinal dystrophies and
one exonic ABCA4 variant. Hum Mutat. 2015;36:43–47.
18. Maugeri A, van Driel MA, van de Pol DJ, et al. The 2588G–>C mutation in
the ABCR gene is a mild frequent founder mutation in the Western
European population and allows the classification of ABCR mutations in
patients with Stargardt disease. Am J Hum Genet. 1999;64:1024–1035.
19. Yatsenko AN, Shroyer NF, Lewis RA, Lupski JR. An ABCA4 genomic
deletion in patients with Stargardt disease. Hum Mutat. 2003;21:636–644.
20. Bauwens M, De Zaeytijd J, Weisschuh N, et al. An augmented
ABCA4 screen targeting noncoding regions reveals a deep intronic
founder variant in Belgian Stargardt patients. HumMutat. 2015;36:39–42.
21. Braun TA, Mullins RF, Wagner AH, et al. Non-exomic and synonymous
variants in ABCA4 are an important cause of Stargardt disease. Hum Mol
Genet. 2013;22:5136–5145.
22. Albert S, Garanto A, Sangermano R, et al. Identification and rescue of
splice defects caused by two neighboring deep-intronic ABCA4 mutations
underlying Stargardt disease. Am J Hum Genet. 2018;102:517–527.
23. Hammond SM, Wood MJ. Genetic therapies for RNA mis-splicing
diseases. Trends Genet. 2011;27:196–205.
24. Collin RW, den Hollander AI, van der Velde-Visser SD, Bennicelli J,
Bennett J, Cremers FP. Antisense oligonucleotide (AON)-based therapy
for Leber congenital amaurosis caused by a frequent mutation in
CEP290. Mol Ther Nucleic Acids. 2012;1:e14.
25. Garanto A, Chung DC, Duijkers L, et al. In vitro and in vivo rescue of
aberrant splicing in CEP290-associated LCA by antisense oligonucleotide
delivery. Hum Mol Genet. 2016;25:2552–2563.
26. Gerard X, Perrault I, Hanein S, et al. AON-mediated exon skipping
restores ciliation in fibroblasts harboring the common Leber congenital
amaurosis CEP290 mutation. Mol Ther Nucleic Acids. 2012;1:e29.
27. Parfitt DA, Lane A, Ramsden CM, et al. Identification and correction of
mechanisms underlying inherited blindness in human iPSC-derived optic
cups. Cell Stem Cell. 2016;18:769–781.
28. Slijkerman RW, Vache C, Dona M, et al. Antisense oligonucleotide-based
splice correction for USH2A-associated retinal degeneration caused by a
frequent deep-intronic mutation. Mol Ther Nucleic Acids. 2016;5:e381.
29. Bonifert T, Gonzalez Menendez I, Battke F, et al. Antisense
oligonucleotide mediated splice correction of a deep intronic mutation
in OPA1. Mol Ther Nucleic Acids. 2016;5:e390.
30. Sangermano R, Khan M, Cornelis SS, et al. ABCA4 midigenes reveal the
full splice spectrum of all reported noncanonical splice site variants in
Stargardt disease. Genome Res. 2018;28:100–110.
31. Hiatt JB, Pritchard CC, Salipante SJ, O'Roak BJ, Shendure J. Single
molecule molecular inversion probes for targeted, high-accuracy
detection of low-frequency variation. Genome Res. 2013;23:843–854.
32. Garanto A, Collin RWJ. Design and in vitro use of antisense
oligonucleotides to correct pre-mRNA splicing defects in inherited
retinal dystrophies. Methods Mol Biol. 2018;1715:61–78.
33. Zernant J, Schubert C, Im KM, et al. Analysis of the ABCA4 gene by next-
generation sequencing. Invest Ophthalmol Vis Sci. 2011;52:8479–8487.
34. Liquori A, Vache C, Baux D, et al. Whole USH2A gene sequencing identifies
several new deep intronic mutations. Hum Mutat. 2016;37:184–193.
35. Vaz-Drago R, Custodio N, Carmo-Fonseca M. Deep intronic mutations
and human disease. Hum Genet. 2017;136:1093–1111.
36. Cornelis SS, Bax NM, Zernant J, et al. In silico functional meta-analysis of
5,962 ABCA4 variants in 3,928 retinal dystrophy cases. Hum Mutat.
2017;38:400–408.
37. Zhang N, Tsybovsky Y, Kolesnikov AV, et al. Protein misfolding and the
pathogenesis of ABCA4-associated retinal degenerations. Hum Mol
Genet. 2015;24:3220–3237.
38. Genome of the Netherlands Consortium. Whole-genome sequence
variation, population structure and demographic history of the Dutch
population. Nat Genet. 2014;46:818–825.
39. Jaakson K, Zernant J, Kulm M, et al. Genotyping microarray (gene chip)
for the ABCR (ABCA4) gene. Hum Mutat. 2003;22:395–403.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License,which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made. The
images or other third party material in this article are included in the article’s
Creative Commons license, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons license and
your intended use is not permitted by statutory regulation or exceeds the
permitted use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/.
© The Author(s) 2019
1Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands. 2Radboud Institute for
Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. 3Donders Institute for Brain, Cognition
and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands. 4Department of Ophthalmology, Radboud
University Medical Center, Nijmegen, The Netherlands. 5Center for Medical Genetics, Ghent University and Ghent University
Hospital, Ghent, Belgium. 6The Rotterdam Eye Hospital and the Rotterdam Ophthalmic Institute, Rotterdam, The Netherlands.
7Department of Medical Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
8Department of Ophthalmology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
9Department of Ophthalmology, Erasmus Medical Center, Rotterdam, The Netherlands. 10Service d′Exploration de la Vision CHU,
Lille, France. 11Institute for Neurosciences of Montpellier INSERM U1051, University of Montpellier, Montpellier, France. 12Centre d′
Etude du Polymorphisme Humain, Fondation Jean Dausset, Paris, France. 13UCL Institute of Ophthalmology, London, UK.
14Moorfields Eye Hospital, London, UK. 15Department of Haematology, University of Cambridge, Cambridge, UK. 16NIHR
BioResource, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK. 17Department
of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK. 18Univ. Lille, Inserm
UMR-S 1172, CHU Lille, Biochemistry and Molecular Biology Department - UF Génopathies, Lille, France. 19Institut für
Humangenetik, Universität Regensburg, Regensburg, Germany. 20Department of Medical Epidemiology and Biostatistics,
Karolinska Institutet, Stockholm, Sweden
ARTICLE SANGERMANO et al
10 Volume 0 | Number 0 | Month | GENETICS in MEDICINE
